Difference between revisions of "Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5 (Q9827)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Volume (P103): 21, #quickstatements; #temporary_batch_1590009084631)
(‎Created claim: title (P93): An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer, #quickstatements; #temporary_batch_1590010982689)
Property / title
 +
An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English)
Property / title: An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English) / rank
 +
Normal rank

Revision as of 22:04, 20 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Schmidt M
    0 references
    0 references
    2010
    0 references
    Ann. Oncol.
    0 references
    21
    0 references
    An open-label randomized phase II study of adecatumumab a fully human anti-EpCAM antibody as monotherapy in patients with metastatic breast cancer (English)
    0 references